This suggests that combining 4SC-202 and lapatinib may limit the growth of lapatinib-resistant HER2+ tumours by re-sensitising cancer cells to lapatinib through the re-expression of PHLDA1 (Figure 5). Here, ERBB2 is linked to cancer.